LABORATORY RESEARCH A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response The authors showed that the traditional grafting of estrogen receptor α positive (ER+) tumor cells into mammary fat pads induces TGFβ/SLUG signaling and basal differentiation when they require low SLUG levels to grow in vivo. [Cancer Cell] Abstract | Graphical Abstract Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors Using transgenic mouse models, cell line-based functional studies, and clinical specimens, researchers showed that cyclin D1/CDK4 mediate resistance to targeted therapy for HER2-positive breast cancer. [Cancer Cell] Abstract | Press Release Loss of miR-203 Regulates Cell Shape and Matrix Adhesion through ROBO1/Rac/FAK in Response to Stiffness Investigators observed that Robo1 ablation in the developing mammary gland compromised actin stress fiber assembly and inhibited cell contractility to perturb tissue morphogenesis, whereas SLIT2 treatment stimulated Rac and increased focal adhesion kinase activity to enhance cell tension by maintaining cell shape and matrix adhesion. [J Cell Biol] Abstract | Editorial | Press Release Cyclophilin D Counteracts P53-Mediated Growth Arrest and Promotes Ras Tumorigenesis Using cellular and in vivo mouse models, the authors demonstrated that cyclophilin D protein upregulation induced by oncogenic Ras through the Raf-1/MEK/ERK pathway has a deterministic role in tumor progression. [Oncogene] Abstract Zoledronic Acid-Encapsulating Self-Assembling Nanoparticles and Doxorubicin: A Combinatorial Approach to Overcome Simultaneously Chemoresistance and Immunoresistance in Breast Tumors Nanoparticle-based zoledronic acid-containing formulation reduced the IC50 of doxorubicin in human and murine chemoresistant breast cancer cells and restored the doxorubicin efficacy against chemo-immunoresistant tumors implanted in immunocompetent mice. [Oncotarget] Full Article Suppression of Spry1 Inhibits Triple-Negative Breast Cancer Malignancy by Decreasing EGF/EGFR Mediated Mesenchymal Phenotype Scientists reported that sprouty 1 (Spry1) is significantly expressed in triple-negative breast cancer (TNBC) specimen and MDA-MB-231 cells. To understand Spry1 regulation of signaling events controlling breast cancer phenotype, they used lentiviral delivery of human Spry1 shRNAs to suppress Spry1 expression in MDA-MB-231, an established TNBC cell line. [Sci Rep] Full Article CLINICAL RESEARCH Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib plus Anastrozole Compared with Anastrozole Alone in Patients with Estrogen Receptor-Positive Breast Cancer Postmenopausal women with newly diagnosed operable estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancers were recruited. Participants were randomly allocated to two weeks of preoperative treatment with anastrozole 1 mg once per day or the combination of anastrozole 1 mg with pictilisib 260 mg once per day. [J Clin Oncol] Abstract Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and Doxorubicin Pharmacokinetics in Asian Breast Cancer Patients Researchers investigated the impact of ABCB5, ABCC5 and RLIP76 polymorphisms on doxorubicin pharmacokinetics in Asian breast cancer patients. [Pharmacogenomics J] Abstract |